DDS 46,XX e síndrome de Antley-Bixler causada por novas mutações no gene da enzima P450 oxidorredutase by Guaragna-Filho, Guilherme et al.
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
Arq Bras Endocrinol Metab. 2012;56/8578
case report
46,XX DSD and Antley-Bixler syndrome 
due to novel mutations in the 
cytochrome P450 oxidoreductase gene 
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SUMMARY
Deficiency of the enzyme P450 oxidoreductase is a rare form of congenital adrenal 
hyperplasia with characteristics of combined and partial impairments in steroidogenic 
enzyme activities, as P450 oxidoreductase transfers electrons to CYP21A2, CYP17A1, 
and CYP19A1. It results in disorders of sex development and skeletal malformations 
similar to Antley-Bixley syndrome. We report the case of a 9-year-old girl who was born 
with virilized genitalia (Prader stage V), absence of palpable gonads, 46,XX karyotype, 
and hypergonadotropic hypogonadism. During the first year of life, ovarian cyst, par-
tial adrenal insufficiency, and osteoarticular changes, such as mild craniosynostosis, 
carpal and tarsal synostosis, and limited forearm pronosupination were observed. Her 
mother presented severe virilization during pregnancy. The molecular analysis of P450 
oxidoreductase gene revealed compound heterozygosis for the nonsense p.Arg223*, 
and the novel missense p.Met408Lys, inherited from the father and the mother, respec-
tively. Arq Bras Endocrinol Metab. 2012;56(8):578-85
SUMÁRIO
A deficiência da enzima P450 oxidorredutase é uma forma rara de hiperplasia congênita da adre-
nal com características de inibição combinada e parcial de enzimas esteroidogênicas, pois a 
enzima P450 oxidorredutase participa da transferência de elétrons para as enzimas CYP21A2, CY-
P17A1 e CYP19A1. Essa deficiência causa um distúrbio do desenvolvimento do sexo e alterações 
esqueléticas semelhantes às da síndrome de Antley-Bixley. Relatamos o caso de uma menina, 
atualmente com 9 anos de idade, que apresentava ao nascimento genitais virilizados (Prader 5) 
sem gônadas palpáveis, com cariótipo 46,XX e hipogonadismo hipergonadotrófico. No primeiro 
ano de vida, foram observados cisto ovariano, insuficiência adrenal parcial e alterações osteoar-
ticulares como leve craniossinostose, sinostose carpal e tarsal e limitação de pronossupinação 
dos membros superiores. Sua mãe apresentou intensa virilização durante a gestação. O estudo 
molecular do gene P450 oxidorredutase revelou a heterozigose composta das mutações nonsen-
se p.Arg223* e da missense nova p.Met408Lys, herdadas do pai e da mãe, respectivamente. Arq 
Bras Endocrinol Metab. 2012;56(8):578-85 
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INTRODUCTION
Cytochrome P450 monooxygenases are enzymes that catalyze the oxidation of several organic 
compounds. Two biochemical classes of P450 en-
zymes have been distinguished in the human genome. 
In the adrenal glands, type I enzymes, located in the 
mitochondria, receive electrons from reduced nico-
tinamide adenine dinucleotide (NADPH) mediated 
by a flavoprotein and an iron-sulfur protein called, re-
spectively, adrenodoxin reductase and adrenodoxin; in 
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turn, type II enzymes are expressed in the endoplas-
mic reticulum and receive electrons from NADPH via 
a single P450 flavoprotein. Cytochrome P450 oxido-
reductase (OMIM *124015; POR) is the only elec-
tron donor flavoprotein for the cytochrome P450 
type II enzyme complex, including the steroidogenic 
17α-hydroxylase/17,20-lyase (CYP17A1), 21-hy-
droxylase (CYP21A2), and aromatase (CYP19A1) (1). 
POR is an 82-kDa membrane-associated protein en-
coded by the POR gene, which is formed by 15 exons 
spanning 32 kb on the 7q11.2 chromosomal band (2). 
Association with the allosteric cytochrome b5 can en-
hance POR activity, as demonstrated by 17,20-lyase 
reactions and some hepatic P450 enzymes (3).
POR deficiency (OMIM #613571; PORD) is a 
rare and complex form of congenital adrenal hyper-
plasia that results from partial and combined impair-
ment of steroidogenic enzymes. This autosomal re-
cessive disorder was described for the first time in 
2004, when mutations in POR encoding gene were 
identified (4,5). PORD has a wide spectrum of clini-
cal signs and symptoms, including partial and com-
bined enzymatic adrenal dysfunction associated 
with disorders of sex development (DSD) in 46,XX 
and 46,XY individuals, and skeletal abnormalities 
of Antley-Bixler syndrome (OMIN #201750) (6). 
Maternal hyperandrogenism and virilization during 
pregnancy can also be observed. Skeletal malforma-
tions observed in many, but not all, patients with 
PORD are considered to be due to impairment of 
enzyme activities involved in sterol synthesis, such 
as 14α-lanosterol demethylase (CYP51A1) and 
squalene epoxidase, disruption of retinoic acid me-
tabolism catalyzed by CYP26 isozymes (6,7), and 
hepatic drug metabolism (8).
To date, the public and private Human Gene Mutation 
Databases report, respectively, 57 and 79 mutations in the 
POR gene (9). Most of them are missense, followed by 
nonsense, splicing, and a couple of deletions. Depending 
on the type of mutation and its location within the POR 
gene, it may reduce CYP17A1, CYP21A2, CYP19A1 ac-
tivities differently. Therefore, POR variants must be stud-
ied separately for each potential P450 target enzyme (10).
Here, we report a 46,XX patient with PORD and 
manifestations of the Antley-Bixler syndrome in whom 
POR gene analysis revealed compound heterozygo-
sis for the nonsense p.Arg223* and the novel mis-
sense p.Met408Lys, inherited from the father and the 
mother, respectively. 
CASE REPORT
A girl, who was the third child of a healthy mother, was 
born at term by vaginal delivery. At birth, she weighed 
2,830 g and her height was 48 cm, with head circum-
ference of 32.5 cm. Due to the virilized genital ap-
pearance, she was assigned as a male. The mother, 
who denied the use of drugs during gestation, re-
ported severe virilization with hirsutism, clitoro-
megaly, and voice deepening (Figure 1A). All these 
signs regressed after delivery. She also reported two 
previous uneventful gestations: a normal girl from her 
first marriage and a healthy boy. 
At the first appointment in our service, the pa-
tient was 8 months old with male assignment. General 
physical examination indicated virilized genitalia with 
Prader stage V and 2.3-cm phallus, without palpable 
gonads; balanic urethral opening and complete fusion 
POR deficiency and Antley-Bixler syndrome
Figure 1. Mother´s (A) and child’s (B) external genitalia 8 months after 
delivery.
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of labioscrotal folds, which were not pigmented, were 
also observed (Figure 1B). No other dysmorphic signs 
or physical alterations were observed. The mother re-
ported that the phallus length had diminished since 
birth. Initial cytogenetic investigation revealed a 46,XX 
karyotype in 30 metaphases analyzed. A 1.1-cm3 uterus 
and gonads with typical ovarian shape were observed 
upon pelvic ultrasonography, with an anechoic homo-
geneous image in the left adnexial region, suggestive of 
a simple ovarian cyst.
The moderate increase of 17-OH progesterone le vel 
and low androgen (DHEA, androstenedione and tes-
tosterone) levels did not confirm either 21-hydroxylase 
or 11b-hydroxylase deficiencies (Table 1). Therefore, 
the first hypothesis considered for the diagnosis was the 
CYP19 deficiency, based on the severe virilization of 
the mother during pregnancy. However, the CYP19 
gene analysis did not confirm such diagnosis. Although 
the etiology of the clinical signs remained undefined, 
when the patient was 18 months old, it was decided to 
reassign the sex from male to female, with the agree-
ment of the family, and feminizing introitoplasty was 
performed. Gonadal biopsy confirmed the presence of 
two normal ovaries.
Almost one year after the first appointment, muta-
tions in the POR gene sequence were investigated. The 
c.667C>T and c.1223T>A nucleotide changes located 
in exon 6 and in exon 10, respectively, were identified 
(Figure 2). The c.667C>T nucleotide change affects 
codon 223, causing a CGA>TGA substitution that 
forms a premature stop codon; whereas the c.1223T>A 
nucleotide change leads to a change in residue 408 
from a methionine (ATG) to a lysine (AAG). Sequen-
cing of the POR gene of her parents indicated that the 
p.Arg223* and p.Met408Lys mutations were inher-
ited from the father and the mother, respectively. The 
biological importance of p.Met408Lys change in the 
structure of the enzyme was investigated by modeling 
the mutant enzyme and comparing it to its wild type. 
Laboratory follow-up from 8 to 105 months is de-
tailed in table 1. She had never presented any abnormal-
ities related to neurological and growth development 
until the age of 64 months, when X-ray examinations 
demonstrated discrete reduction in cephalic diameters, 
Table 1. Hormonal profile of the patient with POR deficiency during the first 105 months of life
Age (months)
8 18
48
67 105
Basal Post ACTH Post hCG
FSH (IU/L)*1 23.3 10.4 1.3 - - 1.2 1.3
LH (IU/L)*2 13.5 0.5 < 0.1 - - < 0.1 < 0.1
ACTH (pg/mL)*3 20.3 26.8 20.9 - - 35.3 42.9
Cortisol (µg/dL)#4 9.0 8.8 7.8 14.3 - 9.1 8.9
17-OH progesterone (ng/mL)#5 11.6 2.9 3.8 13.3 - 6.6 5.0
DHEA (ng/mL)#6 0.6 0.5 1.0 1.1 - 1.1 1.4
Androstenedione (ng/mL)*7 0.2 0.1 0.1 0.5 - 0.1 0.2
Testosterone (ng/mL)*8 < 0.02 < 0.02 <0.02 - 0.09 < 0.02 < 0.02
* Electrochemiluminescence assay; # radioimmunoassay; normal range (pre-pubertal girls): 1 < 0.1 - 3.8; 2 < 0.1 - 1.4; 3 < 46; 4 5.0 - 22.0; 5 0.07 - 1.5; 6 < 2.5; 7 0.05 - 0.5; 8 < 0.2.
Figure 2. Partial electropherograms of POR gene sequencing of a patient 
with POR deficiency. A) The c.667C>T nucleotide change in exon 6 
causes the CGA>TGA substitution at codon 223; an arginine is replaced 
by a stop codon, representing the null mutation p.Arg223*. B) The 
c.1223T>A nucleotide change located in exon 10 causes the ATG>AAG 
substitution in codon 408, leading to the missense p.Met408Lys. The 
p.Arg223* and p.Met408Lys mutations were inherited from the father and 
the mother, respectively.
A
B
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“hammered silver” appearance usually associated to 
craniosynostosis (Figure 3A), and carpal and tarsal syn-
ostoses (Figures 3B and 3C). When she was 7 years 
old, she complained of limited movement of the arms; 
radiological investigation was normal, despite limited 
pronosupination. The score of osteoarticular anomalies 
was 5, according to Krone and cols. (11). 
She had never required hydrocortisone replacement 
therapy, except before and after the two additional sur-
gical procedures that she had been submitted to: vagi-
nal dilation at 5 years of age due to vaginal stenosis and 
endometritis, and clitoroplasty at the age of 6. She is 
now 9 years old, her weight is 31 kg (z = 0.32), height 
133 cm (z = -0.02, within her target height), and head 
circumference 51 cm (slightly below the mean) (Figure 
4A); her bone age is compatible with chronological age, 
she has normal female genitalia with no signs of puberty 
(Figure 4B), and she takes no medications.
Figure 3. Radiographs of the skull (A), left hand (B) and left foot (C) of 
the patient with POR deficiency, showing a shortened diameter of the head 
and hammered-silver appearance (A), carpal synostosis (B), and tarsal 
synostosis (C).
A
A
B
BC
Figure 4. Patient with POR deficiency at 9 years old (A) and her external 
genitalia after genitoplasty (B).
POR deficiency and Antley-Bixler syndrome
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MATERIALS AND METHODS
Samples of peripheral blood leukocytes were obtained 
and genomic DNA extraction was performed by standard 
techniques (12). The 10 exons of CYP19A1 gene and the 
15 exons of the POR gene, as well as exon-intron junc-
tions were amplified by PCR in different fragments. Be-
fore sequencing, each PCR fragment was purified using 
the Wizard® SV Gel and PCR clean-up system (Promega, 
Madison, WI, USA). Further direct sequencing using 
ABI PRISM Big Dye Terminator v3.1 Cycle Sequencing 
Kit (ABI PRISM/PE Biosystems, Foster City, CA, USA) 
was carried out in separated reactions using sense and 
antisense primers. The sequences were obtained in an 
automatic sequencer ABI PRISM 3130 DNA Analyzer 
(ABI PRISM/PE Biosystems). Free software Chromas 
Pro v.1.5 and CLC Sequence Viewer v.6.6.2 were used 
to analyze and compare sequences with the published 
CYP19A1 and POR sequences at Ensembl database 
(ENSG00000137869 and ENSG00000127948, re-
spectively, www.ensembl.org). The structure used in 
modeling analyses for p.Met408Lys mutation was the 
crystallographically-resolved POR structure PDB ID: 
3QE2 (13). Molecular modeling was performed using 
MODELLER web server software. Modelled images 
were examined and edited using a free version of Py-
MOL® and internal contacts were investigated using the 
Millennium STING (CNPTIA-Embrapa, Brazil).
DISCUSSION
A case of PORD caused by the compound heterozy-
gosis for p.Arg223* and p.Met408Lys is reported. 
The p.Arg223* creates a premature stop codon and 
may probably activate nonsense mRNA decay before 
translation. This mutation was described recently in a 
patient who carried p.Arg223* in compound hetero-
zygosis with p.Arg287Pro, which is considered the 
most common POR mutation in Caucasians (14). 
The p.Met408Lys is described here for the first time. 
It is a non-conservative substitution, since it replaces 
the neutral nonpolar hydrophobic methionine residue 
by the basic polar hydrophilic lysine residue at codon 
408. Residue 408 is located at the boundary of flavin 
adenine dinucleotide (FAD) domain and a hinge re-
gion that links FAD domain to flavin mononucleotide 
(FMN) domain (Figure 5A). The alignment of mod-
eled wild-type and mutated POR structures did not 
show differences in protein folding. However, diver-
gences in two disordered regions can be observed in the 
hinges. In the wild-type protein, the Met408 residue is 
in contact with Leu404 and Leu418 (Figure 5B). The 
methionine-to-lysine substitution creates novel internal 
contacts with neighboring residues, such as L389 and 
W422 (Figure 5C). Those four residues, in turn, estab-
lish additional contacts with other residues and with the 
p.Met408Lys mutation (Figure 5D-K). If such modifi-
cations cause disturbances in enzymatic activity should 
be further investigated. However some possibilities can 
be considered based on data in the literature. 
Figure 5. Alignment of structures of wild-type and p.Met408Lys proteins 
(A); FMN domain is denoted in green (dark green = wild-type; light green = 
mutant); FAD domain is denoted in blue (dark blue = wild-type; light blue = 
mutant); and NADPH domain is denoted in yellowish tones (yellow = wild-
type; greenish-yellow = mutant); red and cyan represent the hinge regions 
of the wild-type and mutant proteins, respectively; black arrow points to the 
normal Met408 (purple) and mutated Lys408 (red) residues; dashed lines 
delimit hinge divergences. Internal contacts for residues 408, 389, 404, 
418, and 422 are shown in the left (B, D, F, H, J) and in the right (C, E, G, 
I, K) for the wild-type and mutant proteins, respectively. The color of lines 
and bars below each amino acid represents different chemical interactions: 
hydrophobic (pink), hydrogen bond (rose), aromatic stacking (grey).
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Hamdane and cols. (15) demonstrated that the hinge 
region facilitates electron transfer from FAD to FMN by 
properly aligning and orienting the two flavin domains. 
They conclude that electron flow from FAD to FMN 
and from FMN to CYPs may be regulated by adjusting 
the distance and orientation of the two flavin cofactors. 
Furthermore, their report provided evidence that POR 
enzyme may undergo conformational changes for proper 
electron transfer to its redox partners. As p.Met408Lys 
mutation causes disturbances in the conformational ar-
rangement of the hinge and establishes novel local inter-
actions, it may alter enzymatic activity by modifying the 
conformation of the hinge region, so that the flexibility 
necessary to promote electron transfer is impaired (16).
The reported patient did not present neonatal signs 
of skeletal malformations; however, during childhood, 
she developed a few osteoarticular abnormalities, such 
as carpal and tarsal synostosis, reduced skull diameter 
and “hammered-silver” appearance (suggestive of cra-
niosynostosis), and limited forearm pronosupination, 
indicating that periodic clinical and image evaluations 
were necessary (6,10,11,17,18). Considering that 
p.Arg223* is a null allele in the compound heterozy-
gosis with p.Met408Lys, it can be inferred that the 
residual activity of p.Met408Lys missense carrying al-
lele is defining the patient’s phenotype. Different from 
the most studied p.Ala287Pro and p.Arg457His muta-
tions, which have been frequently observed in Japanese 
patients and are related to severe inborn skeletal mal-
formations (6,10,18), p.Met408Lys seems to be more 
deleterious to POR activity related to the androgenic 
pathway than to skeletal development, since the patient 
presented severe virilizition and no signs of skeletal mal-
formations at birth. Krone and cols. (11) proposed a 
score for the evaluation of osteoarticular manifestations 
in PORD patients. According to this methodology, total 
malformation score (TMS) can vary from 0 to 16. Fol-
lowing this score method, our patient presented TMS 
of 5, which refers to a moderate grade malformations.
PORD may lead to genital ambiguity in both sexes: 
boys may present undervirilization due to inadequate 
testosterone production resulting from CYP17A1 im-
pairment, and genital ambiguity in girls may be the re-
sult of more complex mechanisms, mainly those from 
defective CYP19A1 activity with excessive androgen 
production and activation of the alternative SRD5A1 
and AKR1C pathways, as well as direct conversion of 
17OH-progesterone to dihydrotestosterone (DHT) 
(2,11,19,20). Probably, only CYP19A1 was affected in 
this case, leading severe virilization of both mother and 
child with low testosterone and high 17OH-progester-
one levels.
The literature is still controversial regarding the 
need for daily glucocorticoid replacement in PORD. 
However, most authors agree with drug administra-
tion only in case of moderate to severe stress, especially 
for those patients who do not present adequate corti-
sol response to ACTH stimulus, as was the case of our 
patient (11,18,21-25). Therefore, glucocorticoid was 
only administrated upon stress situations. Mineralocor-
ticoid reposition is not necessary, although deficient 
POR activity may affect CYP21A2 catalyzed reactions 
(11,24).
PORD deficiency differs from other congenital ad-
renal hyperplasias because it affects multiple enzymes, 
leading them to partial activities and resulting in a vari-
able hormonal profile. Upon CYP21A2 activity, there 
are moderately elevated basal and ACTH-stimulated 
17OH-progesterone levels. However, dihydroepian-
drosterone (DHEA), DHEA-sulphate and androstene-
dione levels are generally low or normal due to the low 
17,20-lyase activity of CYP17A1. This hormonal pro-
file, which is usually observed in patients with PORD, 
including this patient, indicates that the 21-hydrox-
ylation activity by CYP21A2 is as diminished as the 
17-hydroxylation activity by CYP17A1 (4,6,18,25).
Puberty is another important aspect to be consid-
ered; however, knowledge regarding its evolution and 
the hormonal profile of patients with PORD is not to-
tally available yet. It seems that male patients spontane-
ously begin and progress to puberty more easily than 
female patients, although both sexes present different 
levels of hypergonadotropic hypogonadism in all re-
ported cases (4,14,17,18,24).
Similar to the patient reported here, the great major-
ity of female patients in pubertal age and infants in mini-
puberty reported in the literature present ovarian cysts 
and hypergonadotropic hypogonadism (14,17,18,24). 
Ovarian cysts are a common finding in females affect-
ed by steroidogenic disorders, have been reported in 
deficiencies of CYP21A2 (26), CYP17A1 (27), STAR 
(28), CYP19A1 (29) and, recently, in POR deficiency 
(14,18,30). A unique mechanism driving ovarian cyst 
development in females affected by PORD, in addition 
to high gonadotropins resulting from estrogen defi-
ciency, might be the disruptive impact of mutant POR 
on sterol synthesis and metabolism. CYP51A1 requires 
electron transfer from POR for catalytic activity, and 
POR deficiency and Antley-Bixler syndrome
Co
py
rig
ht
©
 A
BE
&
M
 to
do
s o
s d
ire
ito
s r
es
er
va
do
s.
584 Arq Bras Endocrinol Metab. 2012;56/8
catalyzes the conversion from lanosterol to meiosis-acti-
vating sterols. Follicular fluid meiosis-activating sterols 
have been shown to be crucial to resume oocyte meiosis 
at puberty, and to support oocyte maturation (31). It is 
suggested in the literature that hormonal replacement 
could ameliorate the presence of polycystic ovaries 
(14,18). Although our patient still have not shown any 
pubertal signs, she presented elevated gonadotropin 
levels and a suggestive image of an ovarian cyst upon 
ultrasonography in the first months of life. 
Concluding, we present a case report on a girl 
with PORD who is compound heterozygous for 
the nonsense p.Arg223* and the novel missense 
p.Met408Lys mutations associated with severe ma-
ternal virilization, 46,XX DSD, partial glucocorti-
coid insufficiency, hypergonadotropic hypogonadism, 
and ovarian cysts during the first year of life, as well as 
late onset features of Antley-Bixler syndrome.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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